{"filing":{"accession_number":"0001398733-26-000033","cik":"0001398733","ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"aqst-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000033/aqst-20260610.htm"},"events":[{"id":5718,"run_id":5010,"accession_number":"0001398733-26-000033","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is Item 5.07 disclosing the final voting results from Aquestive Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents tabulated results for three matters: election of Class II directors (Gregory B. Brown, John S. Cochran, and Abigail L. Jenkins), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance outcomes and auditor appointment.","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5802,"accession_number":"0001398733-26-000033","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is Item 5.07 disclosing the final voting results from Aquestive Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents tabulated results for three matters: election of Class II directors (Gregory B. Brown, John S. Cochran, and Abigail L. Jenkins), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance outcomes and auditor appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:03:20.874779+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5802,"accession_number":"0001398733-26-000033","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is Item 5.07 disclosing the final voting results from Aquestive Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents tabulated results for three matters: election of Class II directors (Gregory B. Brown, John S. Cochran, and Abigail L. Jenkins), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance outcomes and auditor appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:03:20.874779+00:00","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-06-10"}]}